Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice

Nuclear Medicine and Biology

Volumn 26, Issue 7, 1999, Pages 791-794

  Murud, Kristin M ^a   Larsen, Roy H ^a   Bruland, Øyvind S ^b   Hoff, Per ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Astatine 211; Bisphosphonates; Bone seeking radiopharmaceuticals; Normal tissue uptake; Radiotherapy

Indexed keywords

ASTATINE 211; BISPHOSPHONIC ACID DERIVATIVE; IODINE 125; PAMIDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DRUG TARGETING; DRUG TUMOR LEVEL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RADIOTHERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTATINE; BONE AND BONES; DIPHOSPHONATES; FEMUR; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 0032711134     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00047-5     Document Type: Article

References (18)

1. Berei K. and Vasaros L. (1995) Recent advances in the organic chemistry of astatine. Supplement D2. The Chemistry of Halides, Pseudo-Halides and Azides (Edited by Pata S. and Rappoport Z.), pp. 787-816. John Wiley & Sons, New York.
2. Brown I. Astatine-211 Its application in cancer therapy . Appl. Radiat. Isot. 37:1986;789-798.
3. Bruland Ø.S., Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer. 33:1997;1725-1731.
4. 153Sm-EDTMP. A new promising approach. Acta. Oncol. 35:1996;381-384.
5. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 2nd edn. 1995;The Parthenon Publishing Group, New York.
6. Garg P.K., Archer G.E., Bigner D.D., Zalutsky M.R. Synthesis of radioiodinated N-succinimidyl iodobenzoate Optimization for use in antibody labeling . Appl. Radiat. Isot. 40:1989;485-490.
7. Grabenstetter R.J., Cilley W.A.J. Polynuclear complex formation on solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid (I). Complexometric and pH titrations. J. Phys. Chem. 75:1971;676-687.
8. Heins A. and Plöger W. (1980) [Excerpts of Henkel research papers.] Henkel-Referate 16, pp. 19-25. Henkel Chemical Corp., New York.
9. Kellihan M.J., Mangino P.D. Pamidronate. Ann Pharmacother. 26:1992;1262-1269.
10. 211At- labeling of polymer particles for radiotherapy Synthesis, purification and stability . J. Labelled Compd. Radiopharm. 33:1993;977-986.
11. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J. Nucl. Med. 40:1999;1197-1203.
12. 211At reaction. Appl. Radiat. Isot. 47:1996;135-143.
13. Lewington V.J. Cancer therapy using bone-seeking isotopes. Phys. Med. Biol. 41:1996;2027-2042.
14. 125I-labeled amidobisphosphonates. Nucl. Med. Biol. 26:1999;397-403.
15. Guidelines on the Care of Laboratory Animals and Their Use for Scientific Purposes 1. Housing and Care. 1987;UFAW, London.
16. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer. 58:1988;156-160.
17. Wilbur D.S. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconjugates and Radiopharmaceuticals. 4:1991;85-96.
18. Wingen F., Schmahl L. Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. Arzneim.-Forsch./Drug Res. 35:1985;1565-1571.